E2F-1与小细胞肺癌多药耐药及预后的相关性

Correlation of E2F-1 with multidrug resistance and prognosis of small cell lung cancer?鄢

摘要:

摘要：目的  探讨E2F-1在小细胞肺癌（SCLC）多药耐药中的作用及其与预后的关系。方法  检测92例SCLC患者肿瘤组织中E2F-1的表达，分析E2F-1 mRNA表达对患者生存时间的影响，培养人SCLC敏感细胞株H69和多药耐药细胞株H69AR，分为E2F-1过表达组、阴性对照组和空白对照组，检测不同转染组细胞药物敏感性。结果  SCLC组织中E2F-1 mRNA相对表达量与癌旁组织比较，差异有统计学意义（P <0.05）；低表达组患者中位生存时间与高表达组比较，差异有统计学意义（P <0.05）；E2F-1过表达组H69细胞对阿霉素、顺铂和依托泊苷的IC50值与阴性对照组和空白对照组比较，差异有统计学意义（P <0.05），而E2F-1干扰组H69AR细胞对阿霉素、顺铂及依托泊苷的IC50值与阴性对照组和空白对照组比较，差异有统计学意义（P <0.05）。结论  E2F-1在SCLC组织中呈高表达，下调E2F-1可增强多药耐药细胞株H69AR对化疗药物敏感性。

Abstract:

Abstract: Objective To investigate the effect of E2F-1 on multidrug resistance in small cell lung cancer (SCLC) and its relationship with the prognosis. Methods The expression of E2F-1 in the cancerous tissues of 92 patients with SCLC was detected. The effect of the expression of E2F1 mRNA on survival time was analyzed. The human SCLC sensitive cell line H69 and multidrug resistant cell line H69AR were cultured. The cells were divided into E2F-1 overexpression group, negative control group and blank control group, respectively. The drug sensitivity of the cells in different transfected groups were detected. Results The relative expression level of E2F1 mRNA in the SCLC tissues was higher than that in the adjacent tissues (P < 0.05). The median survival time in the low-expression group was longer than that in the high-expression group (P < 0.05). The IC50 values of Doxorubicin, Cisplatin and Etoposide for H69 cells in the E2F-1 overexpression group were higher than those in the negative control group and the blank control group (P < 0.05). The IC50 values of Doxorubicin, Cisplatin and Etoposide for H69AR cells in the E2F-1 interference group were lower than those in the negative control group and the blank control group (P < 0.05). Conclusions E2F-1 is highly expressed in SCLC tissues. Reduced expression of E2F-1 could enhance the sensitivity of multidrug resistant cell line H69AR to chemotherapy.